70% of Patients with Brain Cancer Originating in the Lungs Responded to Tagrisso, Trial Shows
News
Seventy percent of patients with brain cancer that originated in the lungs responded to treatment with Tagrisso (osimertinib), according to a Phase 3 clinical trial. That compared with 31 percent who ... Read more